Hospitalist Doctors in Yuma, AZ Accepting Medicare

9 Hospitalist doctors found. Showing 1 - 9

Ashish Sharma, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2400 S Avenue A, Yuma Regional Medical Center, Yuma, AZ 85364 Phone: 928-336-3213

Dr. Mohammed Abdelghani Gerais, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2851 S Avenue B Bldg 25, Yuma, AZ 85364 Phone: 928-336-2110    Fax: 928-336-2137

Dr. Kristina Marie Diaz, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2500 S 8th Ave Ste 200, Yuma, AZ 85364 Phone: 283-367-0959    Fax: 928-336-7256

Bharat Magu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2400 S Avenue A, Yuma, AZ 85364 Phone: 928-336-3213

Pirkash Kumar, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2400 S Avenue A, Yuma, AZ 85364 Phone: 928-344-2400

Lauren Novitskie, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2400 S Avenue A, Yuma, AZ 85364 Phone: 928-336-1290

Mehran Giblin, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2400 S Avenue A, Yuma, AZ 85364 Phone: 928-344-2000    Fax: 928-336-3215

Abu Areida A Akam, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 2400 S Ave A, Yuma Regional Medical Center, Yuma, AZ 85364 Phone: 928-336-2000

Dr. Nada Alsaiegh, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2400 S Avenue A, Yuma, AZ 85364 Phone: 928-336-1290

News Archive

Excess COVID-19 cases, deaths in the U.S. may be attributable to PM2.5 pollution from wildfires

Thousands of COVID-19 cases and deaths in California, Oregon, and Washington between March and December 2020 may be attributable to increases in fine particulate air pollution (PM2.5) from wildfire smoke, according to a new study co-authored by researchers at Harvard T.H. Chan School of Public Health.

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc, the global specialty biopharmaceutical company, today announced a joint development and commercialization agreement for ACE-031 and other novel molecules targeting the activin receptor type IIB (ActRIIB) pathway. This pathway plays critical roles in regulating the growth of skeletal muscle.

Healthy gut microbiome shown to be important for recovery after heart attack

The community of microorganisms that live in the human gut has been shown to confer all kinds of health benefits. Now, an international team of researchers has shown in mice that a healthy gut microbiome is important for recovery after a heart attack.

Researchers discover potential target genes to halt thyroid cancer progression

Thyroid cancer is a disease with good cure rates in most cases. In 5% of patients, however, the tumor becomes refractory to the available therapies and may spread all over the body, causing death.

Read more Medical News

› Verified 5 days ago